Protagonist Therapeutics (PTGX) Total Liabilities (2015 - 2026)

Protagonist Therapeutics has disclosed Total Liabilities across 12 years of filings, most recently posting $42.0 million for Q1 2026.

• Total Liabilities for Q1 2026 came in at $42.0 million, down 20.9% year-over-year; the trailing twelve-month figure through Mar 2026 was $42.0 million (down 20.9% YoY), and the FY2025 annual result was $53.5 million, down 22.97% from the prior year.
• Total Liabilities came in at $42.0 million for Q1 2026 at Protagonist Therapeutics, down from $53.5 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $73.3 million in Q2 2024 to a low of $21.3 million in Q4 2023.
• The 5-year median for Total Liabilities is $46.5 million (2022), against an average of $46.9 million.
• Across the five-year window, Total Liabilities tumbled 49.07% in 2023 and surged 226.36% in 2024, its largest moves.
• Protagonist Therapeutics' Total Liabilities stood at $32.3 million in 2022, then sank by 34.18% to $21.3 million in 2023, then soared by 226.36% to $69.4 million in 2024, then slipped by 22.97% to $53.5 million in 2025, then fell by 21.49% to $42.0 million in 2026.
• The last three Total Liabilities figures came in at $42.0 million (Q1 2026), $53.5 million (Q4 2025), and $56.3 million (Q3 2025), per Business Quant data.